

Platelet rich plasma-derived microvesicles increased *in vitro* wound healing

F. LOVISOLO¹, F. CARTON¹, S. GINO¹, M. MIGLIARIO², F. RENÒ¹

¹Innovative Research Laboratory for Wound Healing, Health Sciences Department, University Eastern Piedmont, Novara, Italy

²Dental Clinic, Health Sciences Department, University Eastern Piedmont, Novara, Italy

Abstract. – OBJECTIVE: Platelet rich plasma (PRP) is a haemoderivative used in clinical practice for the treatment of hard-to-heal wounds. Platelet (PLT) activation is a key factor in the wound healing process leading to the production of extracellular vesicles. We obtained PRP and PRP-derived microvesicles (PLT-MVs) from healthy donors and compared their pro-healing efficacy in an *in vitro* wound model using human keratinocytes.

MATERIALS AND METHODS: We evaluated PLT-MVs' direct effect on an *in vitro* model of wound healing. PRP, PRP activated using calcimycin, and PLT-MVs separated by high speed centrifugation were added to scratched keratinocyte monolayers. Fluorescein diacetate was used in flow cytometry to distinguish PLTs and PLT-MVs from debris, and then, PLT-MVs were quantified on the basis of relative dimensions (Forward Scatter signals).

RESULTS: Wound areas were measured at time 0 and after 24 hours and they were healed by $24.80 \pm 4.28\%$ in control conditions, while PRP, activated PRP, and PLT-MVs increased closure of $62.94 \pm 0.96\%$, $52.69 \pm 17.20\%$ and $52.76 \pm 9.44\%$, respectively.

CONCLUSIONS: Our results indicate that PRP pro-healing effects were fully replicable by PLT-MVs, suggesting a key role of microvesicles in the healing process and a possible clinical use as an alternative to PRP.

Key Words:

Wound healing, PRP, Microvesicles, Flow cytometry.

Introduction

Haemoderivatives are defined as blood components, such red blood cells, platelets, granulocytes, plasma, clotting factors, etc., used in therapeutic treatments¹. Platelet-rich plasma (PRP) is the plasma fraction of autologous blood enriched

in platelets obtained by centrifugation and used for the treatment of chronic ulcers². Chronic ulcers are spontaneous or traumatic lesions with a delayed or incomplete healing process³.

Wound healing is a dynamic process, leading to tissue repair through three main steps: inflammation, proliferation and remodelling⁴. The inflammatory phase begins after hemostasis, lasts a few days⁵, macrophages and neutrophil granulocytes clean microbial agents and foreign material from the wound bed and they secrete growth factors and cytokines for the following proliferation phase⁶. The proliferative phase is characterized by angiogenesis, reepithelialisation and extracellular matrix deposition⁷. The remodelling phase takes place after about 2 weeks from trauma, lasting for few days/weeks⁶, during this period immature type III collagen is replaced by mature type I collagen through a complex signalling network, repairing the previously damaged structures⁸.

Different clinical therapies are routinely applied to enhance wound repair, such as recombinant growth factors, factors acting in foetal wound-healing processes⁶ and stem cell⁷ administration or biological tissue replacement⁹. Recently, the use of Platelet-Rich Plasma (PRP) has become a simple and relevant therapy for the treatment of hard-to-heal wounds¹⁰ even if its effectiveness and possible adverse effects need more extensive investigation along with its action mechanisms¹¹.

Platelets are able to release microvesicles from their plasma membranes by exocytosis¹² triggered by mechanical and pharmacological stress, hypoxia¹³, or intracellular calcium variations, followed by cytoskeleton changes and lipid membrane asymmetry¹⁴.

Platelet-derived microvesicles (PLT-MVs) are the most abundant microvesicles in human blood,

particularly during inflammation, during which they support the coagulation cascade through their cargo components (functional enzymes, transcription factors, receptors, cytokines, nucleic acids and mitochondria). Moreover, levels of circulatory PLT-MVs result altered during several disease manifestations, such as coagulation disorders, rheumatoid arthritis, systemic lupus erythematosus, cancers, cardiovascular diseases, and infections, pointing to their potential contribution to different diseases¹⁵.

To our knowledge, no studies have focused on the role of PLT-MVs in wound healing. In this study we obtained PRP and PLT-MVs from healthy donors and compared their pro-healing efficacy in an *in vitro* wound model using human keratinocytes.

Materials and Methods

Cell Culture

Human spontaneously immortalized keratinocytes (HaCaT), isolated from human adult skin¹⁶ are rather resistant to transformation *in vitro*. Immortalization has been achieved by SV40 but has resulted in cell lines with altered differentiation. We have established a spontaneously transformed human epithelial cell line from adult skin, which maintains full epidermal differentiation capacity. This HaCaT cell line is obviously immortal (greater than 140 passages were purchased from Cell Line Service GmbH (Eppenheim, Germany). Cells were grown in culture flask (75 cm²) in Dulbecco's Modified Eagle's Medium (DMEM) containing high glucose levels, supplemented with 10% heat inactivated fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (all from Immunological Science, Italy) in a humidified atmosphere containing 5% CO₂ at 37°C. HaCaT cells were seeded into a 12-multiwell plate and incubated in a humidified atmosphere containing 5% CO₂ at 37°C until confluence was reached.

PRP Preparation

Blood samples (16 ml) of 8 healthy subjects (2 males and 6 females) aged 20 to 50 years (33.2 ± 12.9 years old) were collected in vacuette centrifuge tubes with green safety cap containing sodium heparin (CGF K1 P50V, Silfradent S.r.l., Santa Sofia, Italy), after informed consent and after receiving the approval of the Ethic Committee (C.E. 61/10).

Blood small volume was used for complete blood count performed at the Immunotransfusion Service, "Maggiore della Carità" Hospital, Novara, and the average platelet concentration was 283.43±7.48 x 10³ platelet/μL.

PRP has been obtained using the centrifuge MEDIFUGE CGF (Silfradent S.r.l., Santa Sofia, Italy) through a standardized separation PRP protocol performed by this specific centrifuge in an easy and fast way. In fact, after a single standardized centrifugation (PRP cycle) without the addition of exogenous substances, 3 fractions were visible in each tubes: red blood cells in the lower part, Platelet Poor Plasma (PPP) in the upper part, and Platelet Rich Plasma (PRP) between these two fractions.

PRP underwent to a second centrifugation at 800 g for 10 minutes (Refrigerated Microfuge 1-14K, Sigma-Aldrich, Laborzentrifugen GmbH, Osterode am Harz, Germany) and it was suspended in 1 ml of 0.2 μm filtered Phillips Buffer (NaCl 96.5 mM, Glucose 87.5 mM, EDTA 1.1 mM, Tris Base 8.5 mM, MgCl₂ 2 mM, CaCl₂ 2 mM, KCl 3 mM. PH 7.4), a solution of Ca²⁺ that can induce platelet activation and degranulation, at a concentration of 4.0x10⁶ platelets/ml.

The platelet pellet was washed and centrifuged a last time to reduce cellular debris, (400 g x 5 minutes) and finally it was suspended in Phillips buffer. PRP samples (5 ml) were qualitatively checked after any separation using a flow cytometer (FACSCALIBUR, BD Bioscience, San Jose, CA, USA).

PRP Activation

Some PRP samples (4.0x10⁶ platelets/mL) were stimulated with 5 μM calcium ionophore calcimycin (A-23187, Invitrogen by Thermo Fisher, Waltham, MA, USA) diluted in dimethyl sulfoxide (DMSO) at a final concentration of 0.1% for 5 hours at 37°C in an atmosphere at 5% CO₂ to induce PLT-MVs formation¹⁷.

PLT-MVs Isolation

Microvesicles were isolated by centrifugation¹⁸ (20000 g for 40 minutes, room temperature) after platelets activation using a Refrigerated Microfuge 1-14K centrifuge (SIGMA Laborzentrifugen GmbH, Osterode am Harz, Germany). Microvesicles pellet was suspended in 2 ml of 0.2 μm filtered Phillips Buffer. PLT-MVs presence was assessed in every sample using a flow cytometer (FACSCALIBUR, BD Bioscience, San Jose, CA, USA).

Flow Cytometry Analysis of PRP and PLT-MV

PRP, PRP stimulated with calcimycin and PLT-MVs were loaded with Fluorescein Diacetate (FDA, 1 µg/mL) (Sigma Aldrich, St. Louis, MO, USA), the dark for 30 minutes at 37°C in an atmosphere at 5% CO₂ in order to discriminate them from debris¹⁹. The apolar FDA compound was internalized and cleaved to polar Fluorescein by a specific esterase present in PLT and PLT-MVs.

After incubation, the samples were analysed by flow cytometry using a FACS CALIBUR cytometer (BD Bioscience, San Jose, CA, USA) equipped with a 15-mW air-cooled argon ion laser operating at 488 nm. A minimum of 10000 events was collected per sample at a low sample flow rate setting of 12 µl ± 3 µL/min for a good resolution and an precise discrimination between the non-fluorescent noise and fluorescent signals²⁰. The forward (FSC) and side scatter light (SSC) values were collected using a logarithmic scale to display microvesicles' populations. Fluorescein green fluorescence was measured on the FL1 green channel after a 530 nm BP filter and displayed on a four-decade log scale. Data were collected using the CellQuest software (BD Bioscience, San Jose, CA, USA), and then, analysed using Flowing Software 2.5.2 (University of Turku, Finland).

In Vitro Scratch Assay

Cell migration has been evaluated by *in vitro* scratch assay²¹. HaCaT cells were cultured in a 12-wells plate in complete DMEM medium to reach a confluent monolayer. Cell monolayers were then mechanically scratched with a cut yellow tip (diameter = 2 mm), interrupting their contiguity and simulating a wound, and cell debris were washed away with sterile Phosphate-buffered saline solution (PBS). To fix the initial scratch width, some controls were immediately fixed (T-0) using 3.7% formaldehyde, 3% sucrose solution in PBS. A volume of 1 ml of fresh serum free DMEM was added to other samples untreated or a treated with 100 µl of PRP, PRP activated and PLT-MVs solution and incubated at 37°C in a humidified atmosphere containing 5% CO₂ for 24 hours (T-24h).

At the end of the experiment, both control and treated samples were fixed using 3.7% formaldehyde, 3% sucrose solution in PBS, and then, stained with a 1% crystal violet solution. The samples images were recorded by optical mi-

croscopy (AE200 inverted microscopes, Motic, Honk Kong, China, equipped with an Eyepiece MD500-CK AmScope Camera, Irvine, CA, USA) with a 4X magnification.

In vitro wound healing response was evaluated determining the percentage of wound closure of stained samples, compared to samples fixed at time T-0. Wound width has been measured and quantified using Image J software (Wayne Rasband, National Institute of Health, Bethesda, MD, USA) and wound closure has been expressed as mean ± SD values.

Statistical Analysis

Statistical analysis was performed by one-way ANOVA test using R software 4.0.1. *p*-values <0.05 were considered statistically significant.

Results

PRP obtained by blood centrifugation was diluted in Phillips buffer and analyzed by flow cytometry after FDA incubation. Physical signals obtained (FSC and SSC) were collected using a logarithmic scale to observe events as small as 100-1000 nm. The heterogeneous population obtained was a mix of PLT, PLT-MVs and debris (Figure 1-A1).

Quantification of PLT and PLT-MVs detected by flow cytometry was optimize using FDA. In the presence of FDA, we could distinguish between non fluorescent events (debris = not able to convert fluorescein-diacetate in fluorescein because their lack of intact membrane and un-specific esterase) and fluorescent events (PLT and PLT-MVs). Using this strategy, we could also discriminate PLT and PLT-MVs based on their relative dimension (FSC signals) and fluorescence (FL1 signals) (Figure 1-A2).

Events presenting Fluorescein green fluorescence positivity (R-1 region) were used to quantify PLT-MVs on the basis of their FSC signals (R-2 region) (Figure 1-A2). In fact, PLT present in control samples were the 45.67 ± 0.72% of events present in R1 regions while PLT-MVs account for the 54.33 ± 0.79% (R2) (*p*-value < 0.0001).

PLTs stimulated by calcimycin (5 µg/ml) showed a shift towards lower FSC and SSC values (Figure 1 B1) suggesting the activation of PLT-MVs shedding. In fact, the PLT population in R1 region decreased from 45.67 ± 0.72% to




Figure 1. Dot plots FSC-SSC and FSC-FL1 of PRP, PRP activated and PLT-MVs. Representative dot plot FSC-SSC of (A1) untreated PRP, (B1) PRP activated with 5 μ M ionophore calcimycin, (C1) PLT-MVs isolated from activated PRP; representative dot plot FSC-FL1 of (A2) untreated PRP, (B2) PRP activated with 5 μ M ionophore calcimycin and (C2) PLT-MVs isolated from activated PRP. R-1 gate: Fluorescein-positive events (PLTs and MV-PLTs); R-2 gate: PLT-MVs.

19.47 \pm 0.38% while the PLT-MV population reached the 80.53 \pm 0.78% (Figure 1-B2) (p -value < 0.05).

Calcimycin-activated samples were centrifuged to isolate a PLT-MVs enriched population. As shown in Figure 1 C1, we obtained a population presenting low average FSC and SSC values compared to unstimulated and calcimycin-stimulated sample, conceivable with a population enriched in PLT-MVs. In fact, events present in the R2 region reached 89.63 \pm 0.42 % (Figure 1-C2) (p -value < 0.001).

The data show that there is a major quantity of debris in the PLT-MVs analysis graph, due to the additional centrifugation and activation.

The effects of PRP, PRP activated and isolated PLT-MVs on migration ability of HaCaT cells were studied *in vitro* using a scratch assay (Figure 2A).

The scratch areas were measured using Image J software and expressed as % of closure compared to the initial scratch areas (T-0) (Figure 2B). After 24 hours the wound was healed by 24.80 \pm 4.28 % in control conditions, while HaCaT treated with PRP showed an increased closure of 62.94 \pm 0.96 % as expected. PRP activated with

ionophore induced a similar closure percentage (52.69 \pm 17.20%). HaCaT treated only with separated PLT-MVs were able to induce a percentage of closure of 52.76 \pm 9.44%, comparable to that induced by both PRP and PRP activated.

Discussion

Platelet-rich plasma (PRP) is a hemocomponent rich in platelets and growth factors, widely used in clinical practice to accelerate the healing of damaged tissues, such as chronic wounds or ulcerations²². The several methods used to obtain PRP for wound healing therapies still need to be standardized²³ in order to broaden its use. The efficacy of PRP as therapy for hard-to-heal wounds is based on platelet activation during the hemostatic phase of wound healing: platelets in contact with the wound bed, exposed as a result of injury, release growth factors, such as platelet-derived growth factor (PDGF), transformative growth factor (TGF), vascular endothelium growth factor (VEGF), insulin-like growth factor (IGF) and epidermal growth factor (EGF), that modulate wound-healing phases²⁴. Platelet activation has




Figure 2. *In vitro* wound closure after 24-hours incubation. **A**, Representative optical microscopy images of *in vitro* wound healing (scratch) assay. Fixed cells were stained with 1% crystal violet. Magnification = 4 \times . Control samples fixed at time 0 as a reference for measurements (CT T-0). **B**, Quantification of wound closure. Results are expressed as % of wound closure after 24 hours, setting CT T-0 = 0%. * p -value < 0.05, ** p -value < 0.001 and *** p -value < 0.0001.

been associated with the release of microparticles, and interest in their nature has increased in the last few years as they have been identified as microvesicles (MVs) released by shedding from platelets, and their content has been characterized. Platelet-derived microvesicles (PLT-MVs), with a diameter of 100-1000 nm, represent the most abundant group of MVs present in our blood and they are implicated in the transport and delivery of bioactive molecules participating in hemostasis, thrombosis, inflammation, tumorigenesis, angiogenesis, and immunity²⁵. In fact, platelet-derived vesicles can transport cargo limited by plasma membrane, including membrane proteins, cytosolic proteins and RNA²⁶. Moreover, they can activate intracellular signaling pathways and are implicated in wound healing and tissue regeneration²⁷. Levels of PLT-MV circulating in the blood are altered in clotting disorders, rheumatoid arthritis, cancers, cardiovascular disease and infections, highlighting their potential contribution to different diseases and their possible development as a biomarker¹⁵.

Even if platelets participate in wound healing, few or no information is available about the PLT-MVs direct or indirect role in this process, therefore we attempted to elucidate their action using a simple *in vitro* model (scratch assay) adding PRP, activated PRP, and a PLT-MV solution with a purity of more than 90%, to those *in vitro* wounds to assess their ability to stimulate human keratinocyte migration. The analysis of PLT-MV production was performed using a flow cytometry strategy based on the ability of a vital dye (FDA)¹⁹.

Reepithelization is one of the main processes of wound healing caused by the so-called lateral migration of keratinocytes. Our data show that keratinocyte migration is induced in the presence of isolated PLT-MVs, with a potency comparable to that expressed by PRP and ionophore-activated PRP. In fact, the percentage of wound closure induced by PLT-MVs alone is similar to that measured for PRP and activated PRP.

This observation suggests that the PRP-positive effects on wound healing are mediated di-

rectly by PLT-MVs that are produced upon platelet activation by a plethora of stimuli²⁸. From this point of view, an indirect confirmation for our observation has been provided by a study about PRP activation using electrical fields²⁹. In that paper, electrical field application was able to induce a stronger shedding of Annexin V positive particles (PLT-MVs)²⁶ compared to activation mediated by thrombin and TRAP (thrombin receptor-activating peptides). Moreover, medium conditioned by PRP stimulated with the electric field was able to induce proliferation of MCFA10 (non-transformed mammary epithelial cell line) while medium conditioned by thrombin and TRAP failed in promoting cell growth. Based on these findings, PLT-MVs isolated from PRP could be used in a therapeutic approach, to treat chronic wounds as an alternative option instead of PRP. So far, the focus of this kind of research has been concentrated on exosomes (EXs), another vesicle that can be released by platelets and other cells. EXs are released by exocytosis, derive from multivesicular bodies and alpha-granules, present a diameter between 40 to 100 nm, and contain RNAs, miRNAs and bioactive proteins. EXs release is not induced by collagen, nor thrombin, nor calcium ionophore-mediated activation³⁰, moreover they are difficult to observe in flow cytometry because of their dimensions and difficult to eliminate during PLT-MVs preparation. EXs were able to promote wound healing similar to PRP, improve cell proliferation, migration and angiogenesis *via* phosphoinositide 3-kinase (PI3K)-Akt and mitogen-activated protein kinase (MAPK)-Erk signaling, transforming growth factor β (TGF- β) and yes-associated protein (YAP). In our preparations we cannot exclude EXs presence, but the exocytosis of exosomes is not induced by calcium flux³⁰, and moreover, they are a small percentage compared to PLT-MV³¹.

Conclusions

This preliminary work is the first attempt to focus on the effects of PRP-derived PLT-MVs on *in vitro* wound healing to verify their real healing potential and to image a direct clinical use.

Even if further preclinical investigations are necessary to obtain stronger evidence of the PLT-MV potential, these initial data, obtained using standard, easy and fast procedures, seem to be encouraging. In order to fully understand the effects of PLT-MVs on wound healing, 3D-bio-

printed skin model could be used. These complex *in vitro* models can show the cross-talk between different kinds of cells involved in wound healing, such as fibroblasts and keratinocytes, and matrix component deposition and maturation in the presence of PLT-MVs. However, our observations suggest that the positive effects of PRP on wound healing are mediated directly by PLT-MVs that are produced upon platelet activation.

Therefore, the use of highest-purity PLT-MVs, obtained by cell sorting or ultracentrifugation, could help to further test the PLT-MVs pro-healing effect also in animal models and to clarify if the effect could be modulated by age or general health status of patients, or in pathologies that cause wound-healing process alterations.

Conflict of Interest

The Authors declare that they have no conflict of interests.

Acknowledgements

The authors thank Dr. T. Batani from Silfradent Srl (Santa Sofia FC, Italy) for the precious technical and scientific collaboration and for the furniture of materials and MEDI-FUGE CGF centrifuge for this study. Furthermore, the authors thank the Immunotransfusion Service, "Maggiore della Carità" Hospital (Novara, Italy) for the blood counts..

References

- 1) ZAMANI M, YAGHOUBI Y, MOVASSAGHPUR A, SHAKOURI K, MEHDIZADEH A, PISHGAHI A, YOUSEFI M. Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use? *J Cell Physiol* 2019; 234: 17172-17186.
- 2) PRABHU R, VIJAYAKUMAR C, BOSCO CA, BALAGURUNATHAN K, KALAIARASI R, VENKATESAN K, SANTOSH RAJA E, SWETHA T. Efficacy of homologous, platelet-rich plasma dressing in chronic non-healing ulcers: an observational study. *Cureus* 2018; 2: 2145-2155.
- 3) SUTHAR M, GUPTA S, BUKHARI S, PONEMONE V. Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series. *J Biomed Sci*. 2017; 1: 16-26.
- 4) KIM DJ, JANG JH, JANG SS, LEE J. A Novel substance p-based hydrogel for increased wound healing efficiency. *Mol Basel Switz* 2018; 23: 2215-2228.
- 5) ANDASARI V, LÜ D, SWAT M, FENG S, SPILL F, CHEN L, LUO X, ZAMAN M, LONG M. Computational model of wound healing: EGF secreted by fibroblasts promotes delayed re-epithelialization of epithelial keratinocytes. *Integr Biol Quant Biosci Nano Macro* 2018; 10: 605-634.

- 6) HAN G, CEILLEY R. Chronic Wound Healing: A Review of Current Management and Treatments. *Adv Ther* 2017; 34: 599-610.
- 7) WANG PH, HUANG BS, HORNG HC, YEH CC, CHEN YJ. Wound healing. *J Chin Med Assoc* 2018; 81: 94-101.
- 8) HONG L, SHEN M, FANG J, WANG Y, BAO Z, BU S, ZHU Y. Hyaluronic acid (HA)-based hydrogels for full-thickness wound repairing and skin regeneration. *J Mater Sci Mater Med* 2018; 29: 150-161.
- 9) POWERS JG, HIGHAM C, BROUSSARD K, PHILLIPS TJ. Wound healing and treating wounds: Chronic wound care and management. *J Am Acad Dermatol* 2016; 74: 607-625.
- 10) BONFERONI MC, ROSSI S, SANDRI G, CARAMELLA C, DEL FANTE C, PEROTTI C, MIELE D, VIGANI B, FERRARI F. Bioactive Medications for the Delivery of Platelet Derivatives to Skin Wounds. *Curr Drug Deliv* 2019; 16: 472-483.
- 11) ETULAIN J. Platelets in wound healing and regenerative medicine. *Platelets* 2018; 29: 556-568.
- 12) AATONEN M, GRÖNHOLM M, SILJANDER PRM. Platelet-derived microvesicles: multitasking participants in intercellular communication. *Semin Thromb Hemost* 2012; 38: 102-113.
- 13) BADIMON L, SUADES R, FUENTES E, PALOMO I, PADRÓ T. Role of platelet-derived microvesicles as cross-talk mediators in atherothrombosis and future pharmacology targets: a link between inflammation, atherosclerosis, and thrombosis. *Front Pharmacol* 2016; 7: 293-310.
- 14) ITALIANO JE, MAIRUHU ATA, FLAUMENHAFT R. Clinical relevance of microparticles from platelets and megakaryocytes. *Curr Opin Hematol* 2010; 17: 578-584.
- 15) MELKI I, TESSANDIER N, ZUFFEREY A, BOILARD E. Platelet microvesicles in health and disease. *Platelets* 2017; 28: 214-221.
- 16) BOUKAMP P, PETRUSSEVSKA RT, BREITKREUTZ D, HORNUNG J, MARKHAM A, FUSENIG NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. *J Cell Biol* 1988; 106: 761-771.
- 17) AYERS L, KOHLER M, HARRISON P, SARGENT I, DRAGOVIC R, SCHAAP M, NIEUWLAND R, BROOKS SA, FERRY B. Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. *Thromb Res* 2011; 127: 370-377.
- 18) JAYACHANDRAN M, MILLER VM, HEIT JA, OWEN WG. Methodology for isolation, identification and characterization of microvesicles in peripheral blood. *J Immunol Methods* 2012; 375: 207-214.
- 19) NITSCH A, HARALAMBEV L, EINENKEL R, MUZZIO DO, ZYGMUNT MT, EKKERNKAMP A, BURCHARDT M, STOPE MB. Determination of In Vitro membrane permeability by analysis of intracellular and extracellular fluorescein signals in renal cells. *In Vivo* 2019; 33: 1767-1771.
- 20) POSPICALOVA V, SVOBODA J, DAVE Z, KOTRBOVA A, KAISER K, KLEMOVA D, ILKOVICS L, HAMPL A, CRHA I, JANDAKOVA E, MINAR L, WEINBERGER V, BRYJA V. Simplified protocol for flow cytometry analysis of fluorescently labeled exosomes and microvesicles using dedicated flow cytometer. *J Extracell Vesicles* 2015; 4: 25530-25545.
- 21) RENÒ F, MIGLIARIO M, RIZZI M, INVERNIZZI M, CISARI C, CANNAS M. Low concentration amino-bisphosphonates stimulate human keratinocyte proliferation and in vitro wound healing. *Int Wound J* 2012; 9: 442-450.
- 22) TIAN J, CHENG L, CUI X, LEI X, TANG J, CHENG B. Application of standardized platelet-rich plasma in elderly patients with complex wounds. *Wound Repair Regen* 2019; 27: 268-276.
- 23) YUNG YL, FU SC, CHEUK YC, QIN L, ONG MTY, CHAN KM, YUNG PSH. Optimisation of platelet concentrates therapy: composition, localisation, and duration of action. *Asia-Pac J Sports Med Arthrosc Rehabil Technol* 2017; 7: 27-36.
- 24) CHICHARRO-ALCÁNTARA D, RUBIO-ZARAGOZA M, DAMIÁ-GIMÉNEZ E, CARRILLO-POVEDA JM, CUERVO-SERRATO B, PELÁEZ-GORREA P, SOPENA-JUNCOSA JJ. Platelet rich plasma: new insights for cutaneous wound healing management. *J Funct Biomater* 2018; 9: 10-30.
- 25) DOVIZIO M, BRUNO A, CONTURSI A, GRANDE R, PATRIGNANI P. Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications. *Cancer Metastasis Rev* 2018; 37: 455-467.
- 26) TAO SC, GUO SC, ZHANG CO. Platelet-derived extracellular vesicles: an emerging therapeutic approach. *Int J Biol Sci* 2017; 13: 828-834.
- 27) VARON D, HAYON Y, DASHEVSKY O, SHAI E. Involvement of platelet derived microparticles in tumor metastasis and tissue regeneration. *Thromb Res* 2012; 130: S98-S99.
- 28) FLAUMENHAFT R. Formation and fate of platelet microparticles. *Blood Cells Mol Dis* 2006; 36: 182-187.
- 29) FRELINGER III AL, TORRES AS, CAIAFA A, MORTON CA, BERNY-LANG MA, GERRITS AJ, CARMICHAEL SL, NECULAES VB, MICHELSON AD. Platelet-rich plasma stimulated by pulse electric fields: platelet activation, procoagulant markers, growth factor release and cell proliferation. *Platelets* 2016; 27: 128-135.
- 30) GOETZL EJ, GOETZL L, KARLINER JS, TANG N, PULLIAM L. Human plasma platelet-derived exosomes: effects of aspirin. *FASEB J* 2016; 30: 2058-2063.
- 31) HEIJNEN HF, SCHIEL AE, FIJNHEER R, GEUZE HJ, SIXMA JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. *Blood* 1999; 94: 3791-3799.